# CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

> **NCT04050280** · PHASE2 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 39 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, Adult
- Acute Myeloid Leukemia Recurrent
- Acute Myeloid Leukemia, Relapsed, Adult

## Interventions

- **DRUG:** Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)

## Key facts

- **NCT ID:** NCT04050280
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-02
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04050280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04050280, "CLAG-GO for Patients With Persistent, Relapsed or Refractory AML". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04050280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*